Precision BioSciences, Inc. announced on December 18, 2024, that it received Clinical Trial Application (CTA) approval in Hong Kong for its PBGENE-HBV program. This approval expands the ongoing ELIMINATE-B Phase 1 trial for chronic hepatitis B into a new region.
This marks the second CTA approval for PBGENE-HBV in 2024, following the initial clearance in Moldova. The company is actively recruiting patients in Moldova and has begun activating a top infectious disease clinical site in Hong Kong.
PBGENE-HBV is designed to target a viral site prevalent across all HBV genotypes, including those in Asia, aiming to provide broad patient access. The ELIMINATE-B trial is a global, multi-site study expected to report clinical data as it matures throughout 2025, with a U.S. IND anticipated in 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.